Efficacy Study of Apalutamide in High-risk Prostate Cancer Underway
A study is assessing the efficacy of apalutamide combined with GnRH agonist in high-risk prostate cancer patients undergoing radiation therapy.
Company
Pharmaceutical intelligence for Aragon Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.